Search - tctmd.com

Displaying 101 - 120 of 448

Sort: Relevancy | Date

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Daily News

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

L.A. McKeown

July 11, 2023

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

L.A. McKeown

June 21, 2023

News Conference News LINC 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

L.A. McKeown

June 09, 2023

News Conference News LINC 2023

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

L.A. McKeown

June 08, 2023

News Conference News LINC 2023

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

L.A. McKeown

June 07, 2023

News Industry News

Concept Medical’s fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)

June 01, 2023

News Industry News

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

May 01, 2023

News Daily News

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Michael O'Riordan

February 24, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Daily News

Brachytherapy Remains an Option for DES In-Stent Restenosis

Yael L. Maxwell

January 12, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

Presentation TCT 2022

Stent-Free PCI (DCB Only Approach): Insights and Considerations from the SELUTION de NOVO Randomized Control Study

Presenter: Christian M. Spaulding

September 17, 2022

News Industry News

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

September 13, 2022

News Opinion CV Team Dispatch

August 2022 News Roundup

L.A. McKeown

August 01, 2022

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

L.A. McKeown

May 23, 2022

News Conference News SCAI 2022

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

L.A. McKeown

May 22, 2022

Advertisement

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

Concept Medical’s fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Brachytherapy Remains an Option for DES In-Stent Restenosis

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

Stent-Free PCI (DCB Only Approach): Insights and Considerations from the SELUTION de NOVO Randomized Control Study

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

August 2022 News Roundup

High Lp(a) May Predict Risk of CV and Limb Events in PAD

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content